Minutes: Steering Board meeting 12 and 16 February 2021

1. AstraZeneca – Update on Delivery Schedule




- 2. WHO interim recommendations on AstraZeneca COVID-19 Vaccine, outlining that:
 - ➤ While vaccine supplies are limited, it is recommended that priority be given to health workers at high risk of exposure and older people, including those aged 65 or older.
 - Vaccination is recommended for persons with comorbidities that have been identified as increasing the risk of severe COVID-19, including obesity, cardiovascular disease, respiratory disease and diabetes.
 - Countries can refer to the WHO Prioritization Roadmap and the WHO Values Framework as guidance for their prioritization of target groups.

3.

2. Moderna – Update on Delivery Schedule

In a dedicated meeting, Moderna representatives provided an estimated delivery schedule, outlining:

- the gradual increase in volume in January and February;
- Moderna continues to expect to meet the quarterly commitments
- manufacturing ramp up progresses as expected;
 deliveries scheduled for the week on 22 February



The Company provided an updated weekly estimated delivery schedule for each Member State.

Furthermore, the company outlined that:


>

therefore, closer to the delivery dates it would be able to be more precise on the exact delivery date;

;

:

The Commission and MSs showed , outlining that:



The company outlined the very good functioning of the plant, which started production and that it was currently producing . In the context, the company was very confident

The company outlined that the schedule for March would be provided around 20^{th} of February.

Ordinary Steering Board

1. Update on the allocation of doses (Bazaar) activities

Moderna- the distribution of the top-up doses was finalised.

Novavax- the Members were required to provide feedback by cob the following Monday.

Valneva- it was agreed that the

Pfizer/BioNTech –Members were invited to react to the final distribution of doses that was discussed the previous week.

2. Update on ongoing negotiations and on discussions with other companies

Pfizer/BioNTech II -since no MSs had any bank holiday, it was considered that the five-day opt out period would finish as originally foreseen and the contract could be signed the following week.

Novavax- discussions on the contract were ongoing.

Moderna II- clauses of the new PA were discussed and the way forward was agreed among by the SB

The Members agreed to the clauses of the Purchase Agreement and agreed to go ahead with its adoption the following week.

3. Update on the implementation of contracts and deliveries

Pfizer/BioNTech - the company sent a Declaration under the proposition mechanism, to be filled in by those MSs wanting a	sed
Whereas some MSs outlined having	
One MS stressed that it would prefer this period to cover the month of	
One MSs outlined to get the	the Joint
Procurement	

4. COVAX-latest developments


The Commission informed and the SB discussed about:

- ➤ the WHO interim recommendations on AstraZeneca COVID-19 Vaccine, outlining that the next step would be grating the emergency approval;
- ongoing work on the vaccines sharing mechanism;
- ➤ the ongoing work on the Commission's communication to boost capacity production.

Minutes: Steering Board meeting 16 February 2021

An extraordinary Steering Board meeting was convened on 16 February on the Moderna II Purchase Agreement, in order to:

- present the contract and its key elements;
- get the approval of the Steering Board, which would allow finalising the process;
- inform on the next steps in the procedure.



The Members received detailed information of the key elements:

- number of doses: additional purchase of an option to purchase an additional in 2022),
- price, options structure and payment.

The Members States welcomed the content of the contract and agreed to its adoption by the Commission on the following day.

The Purchase Agreement was to be transmitted to the Member States in on following day, which would trigger the five day opt-out period.

None of the Members States indicated any intention to opt out.